Literature DB >> 28027027

Estimating State Transitions for Opioid Use Disorders.

Emanuel Krebs1, Jeong E Min1, Elizabeth Evans2, Libo Li2, Lei Liu3, David Huang2, Darren Urada2, Thomas Kerr1,4, Yih-Ing Hser2, Bohdan Nosyk1,5.   

Abstract

AIM: The aim was to estimate transitions between periods in and out of treatment, incarceration, and legal supervision, for prescription opioid (PO) and heroin users.
METHODS: We captured all individuals admitted for the first time for publicly funded treatment for opioid use disorder (OUD) in California (2006 to 2010) with linked mortality and criminal justice data. We used Cox proportional hazards and competing risks models to assess the effect of primary PO use (v. heroin) on the hazard of transitioning among 5 states: (1) opioid detoxification treatment; (2) opioid agonist treatment (OAT); (3) legal supervision (probation or parole); (4) incarceration (jail or prison); and (5) out-of-treatment. Transitions were conditional on survival, and death was modeled as an absorbing state.
RESULTS: Both primary PO (n = 11,733) and heroin (n = 19,926) users spent most of their median 2.3 y of observation out of treatment. Primary PO users were significantly younger (median age 30 v. 34 y), and a higher percentage were female (43.1% v. 31.5%; P < 0.001), white (74.6% v. 63.1%; P < 0.001), and had completed high school (31.8% v. 18.9%; P < 0.001). When compared to primary heroin users, PO users had a higher hazard of transitioning from detoxification to OAT (Hazard Ratio (HR), 1.65; 95% CI, 1.54 to 1.77), and had a lower hazard of transitioning from out-of-treatment to either detoxification (0.75 [0.70, 0.81]) or OAT (0.90 [0.85, 0.96]).
CONCLUSION: Our findings can be applied directly in state transition modeling to improve the validity of health economic evaluations. Although PO users tended to remain in treatment for longer durations than heroin users, they also tended to remain out of treatment for longer after transitioning to an out-of-treatment state. Despite the proven effectiveness of time-unlimited treatment, individuals with OUD spend most of their time out of treatment.

Entities:  

Keywords:  criminal justice; heroin; opioid use disorder treatment; prescription opioids; state transitions; subdistribution hazard model

Mesh:

Year:  2016        PMID: 28027027      PMCID: PMC5536954          DOI: 10.1177/0272989X16683928

Source DB:  PubMed          Journal:  Med Decis Making        ISSN: 0272-989X            Impact factor:   2.583


  56 in total

1.  Benefit-cost in the California treatment outcome project: does substance abuse treatment "pay for itself"?

Authors:  Susan L Ettner; David Huang; Elizabeth Evans; Danielle Rose Ash; Mary Hardy; Mickel Jourabchi; Yih-Ing Hser
Journal:  Health Serv Res       Date:  2006-02       Impact factor: 3.402

2.  Cross-system data linkage for treatment outcome evaluation: lessons learned from the California Treatment Outcome Project.

Authors:  Yih-Ing Hser; Elizabeth Evans
Journal:  Eval Program Plann       Date:  2008-02-19

3.  Characterizing durations of heroin abstinence in the California Civil Addict Program: results from a 33-year observational cohort study.

Authors:  Bohdan Nosyk; M Douglas Anglin; Mary-Lynn Brecht; Viviane Dias Lima; Yih-Ing Hser
Journal:  Am J Epidemiol       Date:  2013-02-27       Impact factor: 4.897

4.  Adoption of evidence-based clinical innovations: the case of buprenorphine use by opioid treatment programs.

Authors:  Christina M Andrews; Thomas A D'Aunno; Harold A Pollack; Peter D Friedmann
Journal:  Med Care Res Rev       Date:  2013-09-18       Impact factor: 3.929

5.  Observed transition from opioid analgesic deaths toward heroin.

Authors:  Nabarun Dasgupta; Kathleen Creppage; Anna Austin; Christopher Ringwalt; Catherine Sanford; Scott K Proescholdbell
Journal:  Drug Alcohol Depend       Date:  2014-10-18       Impact factor: 4.492

6.  Rates and correlates of mortality amongst heroin users: findings from the Australian Treatment Outcome Study (ATOS), 2001-2009.

Authors:  Shane Darke; Katherine L Mills; Joanne Ross; Maree Teesson
Journal:  Drug Alcohol Depend       Date:  2010-12-03       Impact factor: 4.492

7.  Frailty-based competing risks model for multivariate survival data.

Authors:  Malka Gorfine; Li Hsu
Journal:  Biometrics       Date:  2010-08-05       Impact factor: 2.571

8.  Cost-effectiveness of diacetylmorphine versus methadone for chronic opioid dependence refractory to treatment.

Authors:  Bohdan Nosyk; Daphne P Guh; Nicholas J Bansback; Eugenia Oviedo-Joekes; Suzanne Brissette; David C Marsh; Evan Meikleham; Martin T Schechter; Aslam H Anis
Journal:  CMAJ       Date:  2012-03-12       Impact factor: 8.262

9.  Bridging waitlist delays with interim buprenorphine treatment: initial feasibility.

Authors:  Stacey C Sigmon; Andrew C Meyer; Bryce Hruska; Taylor Ochalek; Gail Rose; Gary J Badger; John R Brooklyn; Sarah H Heil; Stephen T Higgins; Brent A Moore; Robert P Schwartz
Journal:  Addict Behav       Date:  2015-07-29       Impact factor: 3.913

10.  Evidence-based treatment for opioid disorders: a 23-year national study of methadone dose levels.

Authors:  Thomas D'Aunno; Harold A Pollack; Jemima A Frimpong; David Wutchiett
Journal:  J Subst Abuse Treat       Date:  2014-06-10
View more
  5 in total

1.  The costs of crime during and after publicly funded treatment for opioid use disorders: a population-level study for the state of California.

Authors:  Emanuel Krebs; Darren Urada; Elizabeth Evans; David Huang; Yih-Ing Hser; Bohdan Nosyk
Journal:  Addiction       Date:  2017-02-06       Impact factor: 6.526

2.  Opioid agonist treatment and fatal overdose risk in a state-wide US population receiving opioid use disorder services.

Authors:  Noa Krawczyk; Ramin Mojtabai; Elizabeth A Stuart; Michael Fingerhood; Deborah Agus; B Casey Lyons; Jonathan P Weiner; Brendan Saloner
Journal:  Addiction       Date:  2020-02-24       Impact factor: 6.526

3.  Longitudinal trends in nonmedical prescription opioid use in a cohort of rural Appalachian people who use drugs.

Authors:  Jennifer R Havens; Hannah K Knudsen; April M Young; Michelle R Lofwall; Sharon L Walsh
Journal:  Prev Med       Date:  2020-07-09       Impact factor: 4.018

4.  Economic Evaluation in Opioid Modeling: Systematic Review.

Authors:  Elizabeth Beaulieu; Catherine DiGennaro; Erin Stringfellow; Ava Connolly; Ava Hamilton; Ayaz Hyder; Magdalena Cerdá; Katherine M Keyes; Mohammad S Jalali
Journal:  Value Health       Date:  2020-10-26       Impact factor: 5.725

5.  Short-Term Effects and Long-Term Cost-Effectiveness of Universal Hepatitis C Testing in Prenatal Care.

Authors:  Abriana Tasillo; Golnaz Eftekhari Yazdi; Shayla Nolen; Sarah Schillie; Claudia Vellozzi; Rachel Epstein; Liisa Randall; Joshua A Salomon; Benjamin P Linas
Journal:  Obstet Gynecol       Date:  2019-02       Impact factor: 7.623

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.